![Laureano Simón Buela](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Laureano Simón Buela
Chief Executive Officer at Oncomatryx Biopharma SL
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Vazquez Manuel Sanz | M | - |
Oncomatryx Biopharma SL
![]() Oncomatryx Biopharma SL Pharmaceuticals: MajorHealth Technology Oncomatryx Biopharma SL develops drugs for the treatment of cancer. It also develops biological medications and diagnostic kits to treat invasive states of breast cancer and cancer of the pancreas. The company was founded by Manuel Sanz Vazquez and Buela Laureano Simon in 2009 and is headquartered in Derio, Spain. | 15 years |
Olatz Leis Esnaola | F | - |
StemTek Therapeutics SL
![]() StemTek Therapeutics SL BiotechnologyHealth Technology StemTek Therapeutics SL is a biopharmaceutical company. It provides research services portfolio in drug development for cancer treatment. The company offers screening and custom services. StemTek Therapeutics was founded by Angel García Martín, Olatz Leis Esnaola, and Gabriel Inclan Blanco in 2013 and is headquartered in Derio, Spain. | 11 years |
Gabriel Inclan Blanco | M | - |
StemTek Therapeutics SL
![]() StemTek Therapeutics SL BiotechnologyHealth Technology StemTek Therapeutics SL is a biopharmaceutical company. It provides research services portfolio in drug development for cancer treatment. The company offers screening and custom services. StemTek Therapeutics was founded by Angel García Martín, Olatz Leis Esnaola, and Gabriel Inclan Blanco in 2013 and is headquartered in Derio, Spain. | 11 years |
Pedro Esnaola Latasa | M | 58 |
Oncomatryx Biopharma SL
![]() Oncomatryx Biopharma SL Pharmaceuticals: MajorHealth Technology Oncomatryx Biopharma SL develops drugs for the treatment of cancer. It also develops biological medications and diagnostic kits to treat invasive states of breast cancer and cancer of the pancreas. The company was founded by Manuel Sanz Vazquez and Buela Laureano Simon in 2009 and is headquartered in Derio, Spain. | - |
Evelio Perea Borobio | M | - |
Nelum Corp.
![]() Nelum Corp. Pharmaceuticals: MajorHealth Technology Nelum Corp. operates as a clinical stage biopharmaceutical firm. Its focus areas include cancer and fibrosis. The company is headquartered in Durham, NC. | 6 years |
Roberto Constantino Tapia Conyer | M | - |
Patia Europe SL
![]() Patia Europe SL Miscellaneous Commercial ServicesCommercial Services Patia Europe SL is a public health company based in Donostia-San Sebastián, Spain. The Spanish company integrates genetic, metabolomic, and digital tools to facilitate the prevention and control of type 2 diabetes. Patia's team has extensive experience in the fields of molecular biology and genomic medicine, complemented by top-level alliances with prestigious research centers in and the Americas to make the most advanced genomic and technological tools available to the population in the most accessible way. Patia offers a laboratory test called Diabetespredict™, which provides an evaluation of high sensitivity and specificity of the genetic predisposition to develop type 2 diabetes (DT2). Additionally, it offers personalized recommendations based on the patient's genetics. The test has been developed in collaboration with scientists and endocrinologists from the Hospital General de. Patia also works to reduce the effects of the COVID-19 pandemic on people with diabetes. | - |
Ernesto Vega Navarro | M | - |
Patia Europe SL
![]() Patia Europe SL Miscellaneous Commercial ServicesCommercial Services Patia Europe SL is a public health company based in Donostia-San Sebastián, Spain. The Spanish company integrates genetic, metabolomic, and digital tools to facilitate the prevention and control of type 2 diabetes. Patia's team has extensive experience in the fields of molecular biology and genomic medicine, complemented by top-level alliances with prestigious research centers in and the Americas to make the most advanced genomic and technological tools available to the population in the most accessible way. Patia offers a laboratory test called Diabetespredict™, which provides an evaluation of high sensitivity and specificity of the genetic predisposition to develop type 2 diabetes (DT2). Additionally, it offers personalized recommendations based on the patient's genetics. The test has been developed in collaboration with scientists and endocrinologists from the Hospital General de. Patia also works to reduce the effects of the COVID-19 pandemic on people with diabetes. | - |
Connections Chart
Multi-company connection
Statistics
Country | Connections | % of total |
---|---|---|
Spain | 6 | 85.71% |
United States | 1 | 14.29% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Laureano Simón Buela
- Personal Network